Last reviewed · How we verify
morphine and glucagon
morphine and glucagon is a Opioid analgesic + glucagon (hormone) Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Pain management with concurrent hypoglycemia risk or treatment (investigational/institutional use).
Morphine provides opioid analgesia while glucagon raises blood glucose, a combination potentially used to manage pain while preventing opioid-induced hypoglycemia or to address concurrent pain and hypoglycemic episodes.
Morphine provides opioid analgesia while glucagon raises blood glucose, a combination potentially used to manage pain while preventing opioid-induced hypoglycemia or to address concurrent pain and hypoglycemic episodes. Used for Pain management with concurrent hypoglycemia risk or treatment (investigational/institutional use).
At a glance
| Generic name | morphine and glucagon |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Opioid analgesic + glucagon (hormone) |
| Target | Mu-opioid receptor (morphine); glucagon receptor (glucagon) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Morphine acts as a mu-opioid receptor agonist to provide analgesia and pain relief. Glucagon is a peptide hormone that increases blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. This combination may be used in clinical settings where pain management is needed alongside prevention or treatment of hypoglycemia, though such fixed combinations are uncommon in standard practice.
Approved indications
- Pain management with concurrent hypoglycemia risk or treatment (investigational/institutional use)
Common side effects
- Nausea and vomiting
- Constipation
- Dizziness
- Respiratory depression
- Hyperglycemia (from glucagon)
Key clinical trials
- Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (PHASE2, PHASE3)
- Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- morphine and glucagon CI brief — competitive landscape report
- morphine and glucagon updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about morphine and glucagon
What is morphine and glucagon?
How does morphine and glucagon work?
What is morphine and glucagon used for?
Who makes morphine and glucagon?
What drug class is morphine and glucagon in?
What development phase is morphine and glucagon in?
What are the side effects of morphine and glucagon?
What does morphine and glucagon target?
Related
- Drug class: All Opioid analgesic + glucagon (hormone) drugs
- Target: All drugs targeting Mu-opioid receptor (morphine); glucagon receptor (glucagon)
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Pain management / Endocrinology
- Indication: Drugs for Pain management with concurrent hypoglycemia risk or treatment (investigational/institutional use)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing